End of induction patient reported outcomes predict clinical remission and endoscopic improvement with vedolizumab and adalimumab in ulcerative colitis.
Emily Chu Lee WongBadar HasanParambir S DulaiJohn K MarshallWalter ReinischNeeraj NarulaPublished in: Scandinavian journal of gastroenterology (2022)
Post-induction PROs strongly predict the odds of CR and EI in UC and simplified evaluations can be used to assess early response to UC therapies.